Search results
Cheng ML, Lee JK, Kumar R, Klein H, Raskina K, Schrock AB, Michael KS, Mazor T, Cerami E, Oxnard GR, Liu D, Beltran H, Sholl LM, Nishino M, J?nne PA. Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer. JCO precision oncology 2022.
Cheng ML, Lee JK, Kumar R, Klein H, Raskina K, Schrock AB, Michael KS, Mazor T, Cerami E, Oxnard GR, Liu D, Beltran H, Sholl LM, Nishino M, J?nne PA. Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer. Volume 6. JCO precision oncology 2022.
Source for information on Cheng, Michael David 1969- (Michael Cheng, Michael D. Cheng): Contemporary Theatre, Film and Television dictionary.
Feb 18, 2022 · Feb. 18, 2022, 12:30 PM PST. By Tat Bellamy-Walker. A number of student-led groups are speaking out after two posters containing racist messages were stuck on the door of Michael Cheng, president ...
Jul 19, 2016 · “Michael Cheng is a dedicated, detail focused professional. Having known Michael for years - and worked with him on a number of projects - I can absolutely give him my highest recommendation.
- 500+
- Florida International University
- 6.6K
- Miami, Florida, United States
Dr. Michael L. Cheng is a medical oncologist who cares for patients with lung cancer and other tumors affecting the chest, with a particular focus on non-small cell lung cancer. He strives to provide individualized, compassionate care through precision oncology (using the genetic profile of the patient's cancer to custom-tailor treatment).
Michael Cheng, MD Assistant Professor of Clinical Medicine, UCSF. Cancer Center Program Membership Molecular Oncology. Box 3211, UCSF San Francisco, CA 94143
